EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prevention of Transition from Acute Kidney Injury to Chronic Kidney Disease Using Clinical-Grade Perinatal Stem Cells in Non-Clinical Study

Agne Gryguc iD, Justinas Maciulaitis, Lukas Mickevicius, Arvydas Laurinavicius iD, Neringa Sutkeviciene iD, Ramune Grigaleviciute, Vilma Zigmantaite, Romaldas Maciulaitis, Inga Arune Bumblyte

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25179647 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Agne Gryguc und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania. Hauptthemen laut MEDLINE: Acute Kidney Injury, Renal Insufficiency, Chronic, Mesenchymal Stem Cells, Mesenchymal Stem Cell Transplantation. Die Arbeit nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Lithuanian Science Council, Polish National Agency for Academic Exchange.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute kidney injury (AKI) is widely recognized as a precursor to the onset or rapid progression of chronic kidney disease (CKD). However, there is currently no effective treatment available for AKI, underscoring the urgent need for the development of new strategies to improve kidney function. Human placental mesenchymal stromal cells (hpMSCs) were isolated from donor placentas, cultured, and characterized with regard to yield, viability, flow cytometry, and potency. To mimic AKI and its progression to CKD in a rat model, a dedicated sensitive non-clinical bilateral kidney ischemia-reperfusion injury (IRI) model was utilized. The experimental group received 3 × 105 hpMSCs into each kidney, while the control group received IRI and saline and the untreated group received IRI only. Urine, serum, and kidney tissue samples were collected over a period of 28 days. The hpMSCs exhibited consistent yields, viability, and expression of mesenchymal lineage markers, and were also shown to suppress T cell proliferation in a dose-dependent manner. To ensure optimal donor selection, manufacturing optimization, and rigorous quality control, the rigorous Good Manufacturing Practice (GMP) conditions were utilized. The results indicated that hpMSCs increased rat survival rates and improved kidney function by decreasing serum creatinine, urea, potassium, and fractionated potassium levels. Furthermore, the study demonstrated that hpMSCs can prevent the initial stages of kidney structural fibrosis and improve kidney function in the early stages by mitigating late interstitial fibrosis and tubular atrophy. Additionally, a robust manufacturing process with consistent technical parameters was established.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Kidney InjuryRenal Insufficiency, ChronicMesenchymal Stem CellsMesenchymal Stem Cell TransplantationAnimalsHumansRatsFemalePregnancyPlacentaReperfusion InjuryDisease Models, AnimalKidneyRats, Sprague-DawleyMaleDisease Progression

Stichwörter der Autor:innen

acute kidney injurychronic kidney diseaseperinatal stem cellprevention

Autor:innen und Institutionen

  • Department of Nephrology, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.
  • Hospital of Lithuanian University of Health Science, 50161 Kaunas, Lithuania.
  • Institute of Cardiology, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.
  • Institute of Physiology and Pharmacology, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.
  • Department of Urology, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.
  • National Center of Pathology, Affiliate of Vilnius University Hospital Santaros Klinikos, 08661 Vilnius, Lithuania.

ORCID-Profile: Agne Gryguc, Arvydas Laurinavicius, Neringa Sutkeviciene

Förderung

  • Lithuanian Science Council
  • Polish National Agency for Academic Exchange

Zitieren

APA

Gryguc, A., Maciulaitis, J., Mickevicius, L., Laurinavicius, A., Sutkeviciene, N., Grigaleviciute, R., Zigmantaite, V., Maciulaitis, R., & Bumblyte, I. A. (2024). Prevention of Transition from Acute Kidney Injury to Chronic Kidney Disease Using Clinical-Grade Perinatal Stem Cells in Non-Clinical Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25179647

Vancouver

Gryguc A, Maciulaitis J, Mickevicius L, Laurinavicius A, Sutkeviciene N, Grigaleviciute R, et al. Prevention of Transition from Acute Kidney Injury to Chronic Kidney Disease Using Clinical-Grade Perinatal Stem Cells in Non-Clinical Study. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25179647

BibTeX
@article{Gryguc2024,
  author = {Gryguc, Agne and Maciulaitis, Justinas and Mickevicius, Lukas and Laurinavicius, Arvydas and Sutkeviciene, Neringa and Grigaleviciute, Ramune and Zigmantaite, Vilma and Maciulaitis, Romaldas and Bumblyte, Inga Arune},
  title = {Prevention of Transition from Acute Kidney Injury to Chronic Kidney Disease Using Clinical-Grade Perinatal Stem Cells in Non-Clinical Study},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25179647}
}
Kostenlos starten →